PHP
KNSA icon

Parkman Healthcare Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Parkman Healthcare Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5M Sell
259,184
-406,024
-61% -$18M 1.29% 26
2025
Q4 		$27.4M Sell
665,208
-6,384
-1% -$256K 2.61% 9
2025
Q3 		$26.1M Buy
671,592
+182,796
+37% +$5.94M 2.72% 6
2025
Q2 		$13.5M Sell
488,796
-273,825
-36% -$6.97M 1.55% 21
2025
Q1 		$16.9M Sell
762,621
-2,832
-0.4% -$58.3K 2.01% 16
2024
Q4 		$15.1M Buy
765,453
+10,209
+1% +$233K 2.02% 16
2024
Q3 		$18.9M Buy
755,244
+108,102
+17% +$2.63M 2.41% 9
2024
Q2 		$12.1M Buy
647,142
+979
+0.2% +$18.3K 1.62% 21
2024
Q1 		$12.7M Buy
646,163
+30,470
+5% +$595K 1.56% 20
2023
Q4 		$10.8M Buy
615,693
+105,883
+21% +$1.74M 1.52% 21
2023
Q3 		$8.86M Buy
509,810
+218,107
+75% +$3.67M 1.62% 16
2023
Q2 		$4.11M Buy
291,703
+41,446
+17% +$555K 0.71% 44
2023
Q1 		$2.69M Buy
250,257
+58,950
+31% +$777K 0.59% 50
2022
Q4 		$2.87M Buy
191,307
+65,115
+52% +$948K 0.76% 47
2022
Q3 		$1.62M Buy
126,192
+1,484
+1% +$16.9K 0.46% 64
2022
Q2 		$1.21M Buy
124,708
+6,461
+5% +$60.3K 0.44% 56
2022
Q1 		$1.18M Buy
118,247
+4,603
+4% +$48.8K 0.34% 64
2021
Q4 		$1.34M Buy
+113,644
New +$1.4M 0.3% 68
2021
Q2 		– Sell
-80,603
Closed -$1.49M – 91
2021
Q1 		$1.49M Buy
80,603
+5,603
+7% +$115K 0.35% 66
2020
Q4 		$1.32M Buy
+75,000
New +$1.32M 0.34% 70

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Parkman Healthcare Partners's KNSA Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 61% in Q1 2026, selling an estimated $18M and leaving 259,184 shares worth $12.5M. The position accounts for 1.29% of the portfolio, ranked #26.

Parkman Healthcare Partners first reported a position in KNSA in Q4 2020 and has held it in 20 quarters since. The position peaked at $27.4M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Parkman Healthcare Partners held 259,184 shares of Kiniksa Pharmaceuticals worth $12.5M as of Q1 2026.
  • Parkman Healthcare Partners sold 406,024 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $18M.
  • Kiniksa Pharmaceuticals made up 1.29% of Parkman Healthcare Partners's portfolio in Q1 2026, its #26 holding.
  • Parkman Healthcare Partners first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Parkman Healthcare Partners's Kiniksa Pharmaceuticals position peaked at $27.4M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.